Urinary Frequency as a Possibly Overlooked Symptom in COVID-19 Patients: Does SARS-CoV-2 Cause Viral Cystitis?

Jan-Niclas Mumm a,*, Andreas Osterman b,c, Michael Ruzicka d, Clemens Stihl e, Theresa Vilsmaier f, Dieter Munker d, Elham Khatamzas a, Clemens Giessen-Jung d, Christian Stief a, Michael Staehler a, Severin Rodler a

a Klinik und Poliklinik für Urologie, Klinikum der Universität München, Munich, Germany
b National Reference Center for Retroviruses, Max von Pettenkofer Institute and Gene Center, Faculty of Medicine, LMU München, Munich, Germany
c German Center for Infection Research, Munich Partner Site, Munich, Germany
d Medizinische Klinik III, Klinikum der Universität München, Munich, Germany
e Klinik für Hals-Nasen-Ohren-Heilkunde, Klinikum der Universität München, Munich, Germany
f Klinik für Frauenheilkunde, Klinikum der Universität München, Munich, Germany

* Corresponding author. Klinik für Urologie, Klinikum der Universität München, Marchioninistraße 15, 81377 Munich, Germany. Tel. +49 89 440075970; Fax: +49 89 440076532.
E-mail address: janniclas.mumm@med.uni-muenchen.de (J.-N. Mumm).

Keywords: COVID-19; Urinary frequency; Urinary infection; Triage; Viral cystitis

Abstract
The current coronavirus disease 2019 (COVID-19) pandemic is a challenge for physicians in triaging patients in emergency rooms. We found a potentially dangerous overlap of classical urinary symptoms and the as yet not fully described symptoms of COVID-19. After a patient was primarily triaged as a urosepsis case and then subsequently diagnosed with COVID-19, we focused on an increase in urinary frequency as a symptom of COVID-19 and identified this in seven males out of 57 patients currently being treated in our COVID-19 wards. In the absence of any other causes, urinary frequency may be secondary to viral cystitis due to underlying COVID-19 disease. We propose consideration of urinary frequency as an anamnestic tool in patients with infective symptoms to increase awareness among urologists during the current COVID-19 pandemic to prevent fatal implications of misinterpreting urological symptoms.

1. Case series
1.1. Background
After its initial discovery in Wuhan, China the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread throughout the world and the consecutive coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization shortly afterwards [1]. As the pandemic is still in an early phase and many symptoms have not yet been fully described [2], careful clinical observation is of paramount importance. Rocco et al [3]
pointed out the importance of early recognition of symptoms by urologists for proper triage of patients and to prevent missing possible SARS-CoV-2 infection because of an overlap of COVID-19 and classical urological symptoms. We believe that in addition to fever, an increase in urinary frequency should be considered as an important overlapping symptom with urosepsis in the differential diagnosis of COVID-19 both in ambulatory care and in emergency rooms.

2.2. Cases
A case with suspected urinary sepsis was admitted to the emergency department of a university hospital. The patient reported fever, shivering, flank pain, urgency, and increased urinary frequency as initial symptoms. Initial urine analysis via urine sediment and urine culture demonstrated no signs of infection. The patient was discharged home with oral antibiotics. As part of the routine work-up in German hospitals, a nasopharyngeal swab that had been taken on the same day revealed a positive result for SARS-CoV-2 by polymerase chain reaction (PCR) the following day. Subsequently, the patient was admitted to one of our specialized COVID-19 wards with aggravating symptoms including fever, fatigue, and breath-dependent chest pain. Urinary frequency is a common symptom in urinary infection. In order to investigate if this was present in other patients with COVID-19, we retrospectively and prospectively looked at patient histories for the presence of urinary frequency on admission to our specialized COVID-19 wards. In the time period from March 16 to April 13, 2020, seven males out of 57 patients reported an increase in urinary frequency along with dry cough (n = 5), fever (n = 3), and shortness of breath (n = 3) as leading symptoms (Tables 1 and 2). All patients tested positive for SARS-CoV-2 in nasopharyngeal swabs and developed pulmonary symptoms detectable on imaging (Figure 1). Micturition protocol revealed an average of 13.7 micturitions per day on the day of admission and 11.6 on day 5. In all patients, urinary infection, acute renal injury, and prostatitis were excluded by urine analysis and normal serum creatinine and prostate-specific antigen (PSA), respectively. Prostate volumes were evaluated via ultrasound, which revealed mildly enlarged prostates in all patients; there were no signs of residual urine or significant bladder wall thickening. SARS-CoV-2 RNA was not detected by PCR in any urinary specimens taken from all the patients during the first week after admission. Two patients had detectable SARS-CoV-2 RNA in serum during this period (Ct value 40; Tables 3 and 4). None of the patients required admission to the intensive care unit. The average length of stay was 15 d.

2. Discussion
The reason for higher urinary frequency is unclear so far, as the patients had no signs of acute kidney injury, bacterial infection, or prostatitis. We suspect that viral cystitis due to SARS-CoV-2 causes the urinary frequency symptom. It is unclear whether replication of SARS-CoV-2 RNA in urothelial cells or secondary effects due to local or systemic inflammation, such as endotheliitis [4], are a hallmark in COVID-19 patients leading to symptoms such as irritative symptoms of the lower urinary tract and high urinary frequency. Interestingly, three patients presented with microhematuria, which possibly further supports the hypothesis of SARS-CoV-2–induced viral cystitis on infection of urothelial cells. Conversely, we did not detect viral RNA in the urine of these patients, so it seems that urine is unlikely to be a potential source of infection, at least in our cohort.

2.1. Potential mode of action
Recent studies revealed the cell-surface protein angiotensin-converting enzyme 2 (ACE2) as the main receptor for the SARS-CoV-2 spike protein [5]. Investigations of the distribution across many different tissues revealed that ACE2 expression was highest in lung, intestines, and kidney, but it was also high in 2.4% of urothelial cells, potentially increasing their susceptibility to infection with SARS-CoV-2 and possible subsequent viral cystitis [6]. As viral RNA has been detected in urine of COVID-19 patients [7], it can be hypothesized that infection of tissues of the urinary tract might cause an increase in urinary frequency. Detection of SARS-CoV-2 RNA in serum of two hospitalized patients, similar to detection of elevated IL-6 [8], is suggestive of the assumption that urinary frequency occurs as a complication in these patients in the course of a more severe stage of infection. Despite the presence of ACE2 in the urogenital tract, negative urinary PCR results do not support the assumption of strong or even relevant continuous replication in (luminal) tissues of the efferent urinary tract. Since it is unclear whether the receptor is expressed in luminal or basal urothelial cells, the route by which SARS-CoV-2 might cause viral cystitis could be via either viremia from the basal side or urine from the luminal side of urothelial tissue. The absence of viral RNA in urine and the detection of SARS-CoV-2 in serum of two patients might indicate a role of infection in basal urothelial cells via blood that then causes cystitis. In addition, it has been postulated that endotheliitis might play a role in COVID-19 patients [4] and might contribute to local inflammation in the bladder (Fig. 2). Further evidence is urgently needed for a fuller understanding of the possible molecular mechanisms.

2.2. Clinical implications
Classical symptoms of urinary tract infection or urosepsis such as fever and frequent urination might be misleading during the current COVID-19 pandemic. In general, diagnosis of COVID-19 is challenging as patients often present with unclear or even subclinical signs of disease [9]. Contaminated urine samples may hamper accurate interpretation of urine diagnostics. Furthermore, urological patients often have ureteral stents or other prosthetic materials that can lead to infected sediments in urine analysis. As these patients are often elderly or immunocompromised with comorbidities such as cancer or diabetes, they represent a high-risk cohort for both urosepsis and severe COVID-19 disease. We therefore believe that in the current COVID-19 pandemic, laboratory work-up should include blood tests such as full blood count, interleukin-6, ferritin, procalcitonin, PSA (in males), and C-reactive protein, as well as urinary examination (microscopy and culture) and nasopharyngeal swab testing for SARS-CoV-2 RNA. These diagnostic tools may be critical for differentiation between COVID-19 and urological diagnoses in patients presenting with urinary frequency.

2.3. Conclusions
We identified higher urinary frequency as an additional symptom of SARS-CoV-2 infection independent of acute renal injury or urinary tract infection in a small series of hospitalized patients. Since urinary frequency along with clinical signs such as fever and positive laboratory results for inflammatory markers may be misinterpreted as urosepsis, knowledge of this finding is important for urologists during the current COVID-19 pandemic. Further research is warranted to understand the molecular mechanisms leading to urinary frequency, potentially attributed to viral cystitis in SARS-CoV-2–infected patients, and to determine its prognostic value.
Conflicts of interest: The authors have nothing to disclose.

Acknowledgments: We thank all the patients for participating in our study and all the physicians, nurses, and staff involved in the management of COVID-19 patients. We are also grateful for the efforts of Johannes Hellmuth and the team involved in establishing the prospective COVID-19 register at LMU München for providing this research platform for the benefit of patients.

References
1 World Health Organization. Coronavirus disease (COVID-2019) situation reports. World Health Organization Web site. www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
2 Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–9.
3 Rocco B, Sighinolfi MC, Mussini C. COVID-19: importance of the awareness of the clinical syndrome by urologists. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.03.029
4 Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020;395:1417–8.
5 Li W, Sui J, Huang IC, et al. The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2. Virology 2007;367:367–74.
6 Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. In press. https://doi.org/10.1007/s11684-020-0754-0
7 Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20.
8 Herold T, Jurinovic V, Arnreich C, et al. Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. medRxiv In press. www.medrxiv.org/content/10.1101/2020.04.01.20047381v2
9 Song JY, Yun JG, Noh JY, Cheong HJ, Kim WJ. Covid-19 in South Korea—challenges of subclinical manifestations. N Engl J Med. 2020;382:1858–9
10 Guo L, Wei D, Zhang X, et al. Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA score. Front Microbiol 2019;10:275.

Fig. 1 – Lung imaging for all the patients. Computed tomography lung imaging was performed for all patients on admission (±5 d). All patients showed signs of viral pneumonia, as evidenced from the images. (A,B) Images for patient 1 in the coronal and axial planes. (C–H) Images for patients 2–7, respectively, in the coronal plane. Predominantly bilateral ground glass opacification and typical COVID19-associated crazy paving areas are evident (C,F,H). COVID19 = coronavirus disease 2019.

Fig. 2 – Potential mode of action. ACE2 has been described as the receptor for SARS-CoV-2, so urothelial cells might be affected in COVID-19 patients [6]. As localization of expression is unclear so far, basal or luminal expression is possible, so two possible
infection routes could be hypothesized: (1) infection via capillaries is possible, especially in the light of viraemia an infection route of interest; (2) infection via urine might be possible, as SARS-CoV-2 has been detected in urine elsewhere [7]. (3) Alternatively, cystitis might be secondary due to local inflammation (eg, endotheliitis) [4].

ACE2 = angiotensin-converting enzyme 2; COVID19 = coronavirus disease 2019; SARS-CoV-2; severe acute respiratory syndrome coronavirus 2.
### Table 1 – Patient characteristics

| Parameter                                      | Result       |
|------------------------------------------------|--------------|
| Median age, yr (range)                         | 62 (59–78)   |
| Median MuLBSTA score (range) a                 | 9 (6–15)     |
| Male, n (%)                                    | 7 (100)      |
| Chronic underlying condition, n (%)            |              |
| Hypertension                                   | 5 (71.4)     |
| Cardiac disease                                | 2 (28.6)     |
| Obesity                                        | 2 (28.6)     |
| Diabetes                                       | 2 (28.6)     |
| Cancer                                         | 2 (28.6)     |
| Renal disease                                   | 1 (14.3)     |
| Benign prostatic hyperplasia                   | 1 (14.3)     |

*The MuLBSTA score is used to predict 90-d mortality in viral pneumonia [10].*

### Table 2 – Symptoms on admission

| Symptom                     | Patients, n (%) |
|-----------------------------|-----------------|
| Increased urinary frequency | 7 (100)         |
| Dry cough                   | 5 (71.4)        |
| Fever                       | 3 (42.9)        |
| Shortness of breath         | 3 (42.9)        |
| Diarrhea                    | 1 (14.3)        |
| Shivering                   | 1 (14.3)        |

### Table 3 – Pulmonary imaging and virological and laboratory results

| Test                                             | Result       |
|--------------------------------------------------|--------------|
| Atypical pneumonia on computed tomography, n (%) | 7/7 (100)    |
| SARS-CoV-2 RNA nasopharyngeal swab, n (%) a      | 7/7 (100)    |
| SARS-CoV-2 RNA in serum, n (%) a                 | 0/3 (0)      |
| SARS-CoV-2 RNA in serum, n (%) b                 | 2/4 (50)     |
| SARS-CoV-2 RNA in urine, n (%)                   | 0/6 (0)      |
| Mean prostate volume, ml (range)                 | 53 (35–66)   |
| Mean residual urine, ml (range)                  | 14.3 (0–40)  |
| Mean urine osmolarity, mosm/kg (range) a         | 547.6 (383–702) |
| Mean prostate-specific antigen, ng/ml (range) a  | 1.47 (0.3–3.6) |
| Mean creatinine, mg/dl (range) a                 | 0.92 (0.7–1.4) |
| Mean creatinine, mg/dl (range) b                 | 0.87 (0.6–1.6) |
| Mean maximum IL-6, pg/ml (range)                 | 215 (26.3–1086) |
| Mean procalcitonin, ng/ml (range) a              | 0.1 (>0.1–0.4) |
| Mean lactate dehydrogenase, U/l (range) a        | 334 (223–565) |
| Mean leukocytes, g/l (range) a                    | 5.9 (2.8–9.7) |
| Mean neutrophils, % (range) a                     | 64 (41–92)   |
| Mean lymphocytes, % (range) a                     | 18 (6–30)    |
| Mean eosinophils, % (range) a                     | 0.7 (<1–2)   |

*Day 0–5.*

*Day 5–10.*

### Table 4 – Standard urinary analysis

| Patients, n (%) |
|-----------------|
| Urinary infection | 0/7 (0) |
| Urine dipstick   |        |
| Negative for leukocytes | 7/7 (100) |
| Urine sediment   |        |
| Negative for leukocytes | 2/4 (50) |
| Condition                              | Count   | Percentage |
|---------------------------------------|---------|------------|
| 1–3 leukocytes per high-power field   | 2/4 (50)|            |
| Microhematuria                        | 3/4 (75)|            |
| Urine cultures negative *             | 6/6 (100)|           |

* Urine culture was not performed for one patient for whom the urine dipstick and urine sediment were negative for leukocytes.
Supplementary material

Methods
All patients with SARS-CoV-2 infection admitted to our hospital are prospectively enrolled in a database. Patients were admitted to specialized COVID-19 wards. Informed consent was received from all participants. Before initiation of the study, the local ethics committee (Ethikkommission der Ludwig-Maximilian-Universität-München) revised the project design and granted approval (reference number: 20-245).

Ultrasound was performed by a urologist to determine the size of the prostate and residual urine volume. Micturition protocols were used to confirm urinary frequency. All urine and blood tests were performed at our central laboratory (Ludwig-Maximilian-Universität München). The standard procedure for urinary testing at our institution is to perform a dip stick test. Additional urine microscopy is performed in severe cases to rule out infection. As urinary cultures are not standard for cases with normal dip stick tests, we performed additional urinary cultures to exclude urinary infection. Testing for SARS-CoV-2 RNA in urine and serum was performed at the Max von Pettenkofer Institute of Virology (Ludwig-Maximilian-Universität München) following routine diagnostic methods and using the N1 primer set from the Centers for Disease Control against a nucleocapsid region [1].

References
[1] Centers for Disease Control and Prevention. 2019-novel coronavirus (2019-nCoV) real-time rRT-PCR panel primers and probes. www.cdc.gov/coronavirus/2019-ncov/downloads/rt-PCR-panel-primer-probes.pdf